you, you said that really well. It is really having access to care. Because when we know that it's out there, then we can access it. But it goes back that there are certain barriers that are different communities, even though they do know they have access to they may face repercussions because they're accessing this care. And I mean a great example, there is a study where we're looking to invest in molecular surveillance. And what that means is when I get my blood drawn my blood like cold, it's like a blueprint. It's my genetic. So if there was an HIV outbreak here in Bloomington, and my genetic code was discovered in that cluster, that information can either be used in my favor, or it can either be used against me. And when I mean in my favor, I mean, hey, Dion, there was an HIV outbreak, and we're calling to let you know that you should go get tested. And what it can be used against me is if I'm fear of disclosure, if I don't disclose this, and someone who was was involved in that cluster, that I potentially may be involved in, can go to law enforcement and say, this individual intentionally put me at harm, and nine times out of 10, that individual who is HIV positive will will face legal actions immediately. And I think we have to look at a lot of things when we talk about access to care, because it is a great thing. But at the same time, we need to figure out how access to care looks like for each demographic, and each community in that it's equal. I'm still learning a little bit of it myself. But the study itself, the action, or what it's called, is called molecular surveillance. And so what that is using myself as an example, is when I go and get my blood drawn every six months to make sure that my liver, kidneys, and liver levels aren't affected by the antiviral medication that I'm on, that my CD for account is in the proper range that my viral load is remaining undetectable, which means below account that these really comprehensive tests can't really detect. When I go and get those done. They have my genetic code, which is, by this blood sample, we can identify this as Dion, this is a certain blood type that belongs to this person, this individual. When you have that, and you have that when multiple individuals who come in, get their labs done who are HIV positive, you now have a collection of that data of that information. As of now, I believe the state currently is determining if it wants to pursue and invest in that route, if that's something that's useful, but I think a lot of us at a grassroot level, can see that as invasive, unethical, and in some ways it, it can help. You know, it can get people into care. In my speech, I use one of the examples of Personally, myself, a local health facility had contacted me and informed me that I was out of care because my paperwork had not been reported to the state, the state has a procedure where you're determined out of care, close to a year, then they have these officers, for lack of better words, surveillance officers contact you, you may not know who they are, but they contact you and ask you, Hey, are you out of care? What can we do to get you back from care? I think that's a really great tool. I think that's something that is very helpful. That is separate from molecular surveillance, however. So just using that as an example, if, if that were to happen, and they discovered that there was an HIV outbreak, and it has my genetic code in that cluster, a neck exposure, and they know that I'm already HIV positive, and someone who is HIV negative then goes to law enforcement and say, Hey, this individual had put me at risk of HIV. It's a charge, it's unlawful to put someone at risk of HIV.